Summary Highlights:
- Gilead Sciences (GILD, Financial) surpasses EPS expectations amidst revenue shortfall, showcasing mixed financial results.
- Analysts forecast a modest upside for Gilead with a consensus rating of "Outperform."
- GuruFocus estimates indicate potential fair value downside, suggesting cautious optimism.
Gilead Sciences Inc. (GILD) announced its most recent quarterly earnings, presenting a Non-GAAP EPS of $1.81, which beat market predictions by $0.04. Despite this earnings success, the company's revenue amounted to $6.67 billion, falling short of expectations by $140 million. This points to a period of mixed financial performance for the renowned biotech firm.
Wall Street Analysts Forecast
Analysts have provided one-year price targets for Gilead Sciences Inc. (GILD, Financial) with an average target price of $112.27. The high estimate reaches $140.00, while the low estimate stands at $82.00. This average target represents a potential upside of 5.77% from the current stock price of $106.15. Investors can explore more in-depth estimates on the Gilead Sciences Forecast page.
The consensus recommendation from 30 brokerage firms rates Gilead Sciences Inc. (GILD, Financial) at 2.1, which corresponds to an "Outperform" classification. Notably, this rating scale ranges from 1 (Strong Buy) to 5 (Sell), positioning Gilead favorably in investor evaluations.
According to GuruFocus estimates, the forecasted GF Value for Gilead Sciences Inc (GILD, Financial) in one year's time is estimated to be $80.51. This suggests a potential downside of 24.15% from its current trading level of $106.15. The GF Value metric represents GuruFocus' fair value estimate, derived from historical trading multiples, past business growth, and projected future performance. For further insights, visit the Gilead Sciences Summary page.
